From Our Newsroom

Cordance Medical Announces Agreement with Stanford Medicine’s Airan and Williams Labs for Precision Neuropsychiatry with Ultrasonic Drug Uncaging Technology

Cordance Medical Accepted into Prestigious FDA TAP Program for its NeuroAccess Device

Cordance Medical’s NeuroAccess Receives FDA Breakthrough Device Designation for Liquid Biopsy in Brain Tumors

Cordance Medical Joins BLOODPAC to Enable Blood-Based Liquid Biopsy Tests for Brain Tumor Patients

Cordance Medical Licenses Key Intellectual Property from Washington University to Enhance its NeuroAccess™ Platform

Noninvasive, ultrasound-based brain biopsy is feasible, safe in people

Cordance Medical and EXACT Therapeutics Announce Strategic Partnership to Revolutionize Drug Delivery to the Brain

Cordance Medical Welcomes Esteemed Experts Eric Leuthardt, MD, and Hong Chen, PhD, to Advance NeuroAccess Technology for Liquid Biopsy and Drug Delivery in Brain Diseases

Cordance Presents Preclinical Data at the International Society for Therapeutic Ultrasound Symposium

Cordance Demonstrates Multi-Site Blood-Brain Barrier Openings in Pre-Clinical Study

Cordance Medical Successful in Pre-Clinical Studies

Cordance Medical Awarded United States Patent for Methods in Opening the Blood-Brain Barrier

Cordance Medical technology presented at the Society for Neuro-Oncology Annual Meeting

Cordance Medical accepted into Endless Frontier Labs Deep Technology Accelerator

Cordance Medical accepted into Creative Destructive Labs Neurology Accelerator

Cordance Medical awarded Phase II National Science Foundation Award

Cordance Medical appoints Ryan Dittamore as Chief Executive Officer

Focused Ultrasound Drug Delivery Efficacy References

Focused Ultrasound Safety References